AZN

AstraZeneca PLC [AZN] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

AZN Stock Summary

Top 10 Correlated ETFs

AZN


Top 10 Correlated Stocks

AZN


In the News

09:27 28 Mar 2024 AZN

AstraZeneca CEO Soriot on Pharmaceuticals in China

AstraZeneca CEO Pascal Soriot discusses the drugmaker's business strategy in China, the US “BIOSECURE Act,” and future deals and partnerships in China. He speaks with Stephen Engle on the sidelines of the BOAO forum.

06:56 28 Mar 2024 AZN

Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts

In the most recent trading session, Astrazeneca (AZN) closed at $66.33, indicating a +0.71% shift from the previous trading day.

11:01 28 Mar 2024 AZN

AstraZeneca's (AZN) Ultomiris Gets FDA Nod for New Indication

FDA approves AstraZeneca's (AZN) Ultomiris for AQP4 Ab+ NMOSD, making it the first and only long-acting C5 complement inhibitor approved for this rare neurological disease.

01:07 28 Mar 2024 AZN

2 More Potential Biotech Buyout Targets

M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot and active area for deal volume, with global sales projected to reach $375 billion by 2027. Today, we profile two smaller oncology names that appear to be logical acquisitions for larger concerns that want to expand their oncology footprints.

03:41 28 Mar 2024 AZN

3 Stagnating Blue-Chip Stocks Ready to Awaken and Soar

In my view, a sure-shot way of minting money from the markets is buying and holding with patience. Of course, the idea needs to be well-researched as a first step.

12:51 28 Mar 2024 AZN

AstraZeneca (AZN) to Buy Fusion Pharmaceuticals for $2.4B

AstraZeneca (AZN) has offered to acquire Fusion for $21.00 per share in cash plus a contingent value (CV) payment of $3.00 per share.

01:00 28 Mar 2024 AZN

AstraZeneca: Fusion acquisition will be a cost effective-investment that can improve cancer outcomes

Dr. Susan Galbraith, executive vice-president of oncology and R&D at AstraZeneca, discusses the healthcare giant's $2.4bn acquisition of Fusion Pharmaceuticals.

06:56 28 Mar 2024 AZN

Astrazeneca (AZN) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Astrazeneca (AZN) closed at $65.86 in the latest trading session, marking a +0.02% move from the prior day.

02:51 28 Mar 2024 AZN

AstraZeneca (AZN) Follows Boehringer, to Cap Inhaler Cost in US

AstraZeneca (AZN) plans to lower the prices of its inhaled respiratory products to $35 per month in the United States. However, the company intends to start this in June 2024.

10:50 28 Mar 2024 AZN

Biotech Stock Soars on AstraZeneca Buyout

Fusion Pharmaceuticals Inc (NASDAQ:FUSN) stock is skyrocketing today, after news that AstraZeneca (AZN) is acquiring the Canadian biotech company for $2.4 billion, or $21 per share.

AZN Financial details

Company Rating
Strong Buy
Market Cap
205.39B
Income
5.96B
Revenue
45.81B
Book val./share
12.54
Cash/share
1.88
Dividend
1.45
Dividend %
2.1%
Employees
83.5K
Optionable
Yes
Shortable
Yes
Earnings
08 Feb 2024
P/E
36.21
Forward P/E
10.23
PEG
4.41
P/S
4.75
P/B
5.74
P/C
36.31
P/FCF
30.62
Quick Ratio
0.18
Current Ratio
0.79
Debt / Equity
0.73
LT Debt / Equity
0.59
-
-
EPS (TTM)
1.93
EPS next Y
6.67
EPS next Q
0.97
EPS this Y
81.13%
EPS next Y
245.5%
EPS next 5Y
201.04%
EPS last 5Y
30.36%
Revenue last 5Y
13.44%
Revenue Q/Q
4.63%
EPS Q/Q
-31.11%
-
-
-
-
SMA20
1.78%
SMA50
-3.3%
SMA100
4.44%
Inst Own
11.27%
Inst Trans
0.72%
ROA
6%
ROE
16%
ROC
0.1%
Gross Margin
80%
Oper. Margin
15%
Profit Margin
13%
Payout
76%
Shs Outstand
3.1B
Shs Float
1.54B
-
-
-
-
Target Price
80.5
52W Range
60.47-76.56
52W High
-10.18%
52W Low
+13.77%
RSI
63.98
Rel Volume
1.34
Avg Volume
6.26M
Volume
8.41M
Perf Week
3.66%
Perf Month
11.85%
Perf Quarter
2.46%
Perf Half Y
-0.99%
-
-
-
-
Beta
0.185
-
-
Volatility
0.81%, 1.37%
Prev Close
2.91%
Price
68.26
Change
3.03%

AZN Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
9.3710.1413.1114.2214.66
Net income per share
0.511.220.041.051.91
Operating cash flow per share
1.141.832.093.143.31
Free cash flow per share
0.20.841.322.322.1
Cash per share
2.393.042.242.051.88
Book value per share
5.045.9513.7611.8712.53
Tangible book value per share
-6.88-6.53-8.09-7.07-6.07
Share holders equity per share
5.045.9513.7611.8712.53
Interest debt per share
7.568.2611.249.89.67
Market cap
129.74B131.27B166.25B211.54B210.4B
Enterprise value
142.59B143.82B190.7B234.6B233.18B
P/E ratio
97.1841.071.48K64.3435.33
Price to sales ratio
5.324.934.444.774.59
POCF ratio
43.727.3527.8821.5720.34
PFCF ratio
254.8859.8644.1829.2332.04
P/B Ratio
9.888.44.235.715.38
PTB ratio
9.888.44.235.715.38
EV to sales
5.855.45.15.295.09
Enterprise value over EBITDA
20.3217.1825.2125.1516.76
EV to operating cash flow
48.0329.9731.9823.9222.54
EV to free cash flow
280.1465.5850.6832.4235.51
Earnings yield
0.010.0200.020.03
Free cash flow yield
00.020.020.030.03
Debt to equity
1.391.30.780.790.73
Debt to assets
0.30.310.290.30.28
Net debt to EBITDA
1.831.53.232.471.64
Current ratio
0.860.961.160.860.82
Interest coverage
2.043.950.812.795.16
Income quality
1.921.23-22.53.921.5
Dividend Yield
0.030.030.020.020.02
Payout ratio
2.691.1234.431.330.75
Sales general and administrative to revenue
00000
Research and developement to revenue
0.240.230.260.220.24
Intangibles to total assets
0.530.490.590.610.57
Capex to operating cash flow
-0.83-0.54-0.37-0.26-0.37
Capex to revenue
-0.1-0.1-0.06-0.06-0.08
Capex to depreciation
-0.65-0.83-0.34-0.47-0.77
Stock based compensation to revenue
0.010.010.020.010
Graham number
7.6312.763.4916.7823.18
ROIC
0.070.11-0.010.070.1
Return on tangible assets
0.050.0900.090.14
Graham Net
-13.48-14.03-16.51-13.86-13.83
Working capital
-2.55B-763M3.65B-3.7B-5.49B
Tangible asset value
-17.91B-17.15B-23.1B-22.07B-18.97B
Net current asset value
-31.22B-31.55B-39.83B-36.83B-36.9B
Invested capital
1.391.30.780.790.73
Average receivables
2.55B5.42B8.2B10.34B11.74B
Average payables
13.41B14.89B17.36B18.99B11.15B
Average inventory
3.04B3.61B6.5B6.84B5.06B
Days sales outstanding
77.5577.49104.9481.66107.98
Days payables outstanding
1.04K1.09K555.79560.86144.23
Days of inventory on hand
236.83277.18263.63138.42239.45
Receivables turnover
4.714.713.484.473.38
Payables turnover
0.350.340.660.652.53
Inventory turnover
1.541.321.382.641.52
ROE
0.10.200.090.15
Capex per share
-0.95-0.99-0.77-0.82-1.21

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
3.593.493.663.683.85
Net income per share
0.290.580.580.440.31
Operating cash flow per share
0.7710.5510.76
Free cash flow per share
0.590.530.40.720.46
Cash per share
2.052.071.861.641.88
Book value per share
11.8811.4711.9811.9212.54
Tangible book value per share
-7.08-7.53-6.69-6.54-6.08
Share holders equity per share
11.8811.4711.9811.9212.54
Interest debt per share
9.4910.219.79.289.3
Market cap
211.4B216.56B223.3B211.29B210.27B
Enterprise value
234.47B241.83B247.47B234.99B233.05B
P/E ratio
58.6630.0330.7138.4454.76
Price to sales ratio
18.8619.9119.5618.3917.49
POCF ratio
88.1669.12129.9867.8588.35
PFCF ratio
114.64130.22180.8194.54146.63
P/B Ratio
5.716.055.975.685.37
PTB ratio
5.716.055.975.685.37
EV to sales
20.9222.2321.6820.4519.38
Enterprise value over EBITDA
206.0362.298.2470.6580.11
EV to operating cash flow
97.7877.19144.0575.4697.92
EV to free cash flow
127.15145.42200.38105.14162.52
Earnings yield
00.010.010.010
Free cash flow yield
0.010.010.010.010.01
Debt to equity
0.790.880.80.770.73
Debt to assets
0.30.330.310.30.28
Net debt to EBITDA
20.276.59.67.137.83
Current ratio
0.860.90.870.790.82
Interest coverage
-0.956.985.74.983.02
Income quality
3.081.390.821.882.65
Dividend Yield
00.0100.010
Payout ratio
01.690.011.030
Sales general and administrative to revenue
00.370.440.42-1.15
Research and developement to revenue
0.230.240.230.220.26
Intangibles to total assets
0.610.610.60.60.57
Capex to operating cash flow
-0.23-0.47-0.28-0.28-0.4
Capex to revenue
-0.05-0.14-0.04-0.08-0.08
Capex to depreciation
-0.37-0.98-0.38-0.69-1.08
Stock based compensation to revenue
0.060000
Graham number
8.7912.2112.5310.879.31
ROIC
-0.010.030.030.020.02
Return on tangible assets
0.020.050.050.040.02
Graham Net
-13.86-14.05-13.41-13.5-13.84
Working capital
-3.7B-2.59B-3.54B-6.09B-5.49B
Tangible asset value
-22.07B-23.48B-20.87B-20.41B-18.97B
Net current asset value
-36.83B-38.61B-36.29B-36.36B-36.9B
Invested capital
0.790.880.80.770.73
Average receivables
10.04B10.36B11.36B11.96B12.77B
Average payables
18.37B19.13B19.47B20.14B11.9B
Average inventory
4.89B4.83B5.01B5.17B5.36B
Days sales outstanding
79.6989.3294.0793.95101.44
Days payables outstanding
590.9907.56906.34882.47127.4
Days of inventory on hand
145.83234.66231.93227.34211.51
Receivables turnover
1.131.010.960.960.89
Payables turnover
0.150.10.10.10.71
Inventory turnover
0.620.380.390.40.43
ROE
0.020.050.050.040.02
Capex per share
-0.18-0.47-0.15-0.28-0.3

AZN Frequently Asked Questions

What is AstraZeneca PLC stock symbol ?

AstraZeneca PLC is a GB stock and trading under the symbol AZN

Is AstraZeneca PLC buy or a sell ?

4 stock analysts have 4 predictions with a medium analyst target price of $78.5. The lowest prediction is $75 and the highest is $82

What is AZN stock prediction ?

What is AstraZeneca PLC stock quote today ?

AstraZeneca PLC stock price is $68.26 today.

Is AstraZeneca PLC stock public?

Yes, AstraZeneca PLC is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap